NMR analysis of lipoprotein particle size does not increase sensitivity to the effect of soy protein on CVD risk when compared with the traditional lipid profile

Applied Physiology, Nutrition and Metabolism

Volumn 33, Issue 3, 2008, Pages 489-500

  Santo, Antonio S ^a   Cunningham, Ariana M ^b   Alhassan, Sofiya ^c   Browne, Richard W ^d   Burton, Harold ^e   Leddy, John J ^e   Grandjean, Peter W ^f   Horvath, Steven M ^e   Horvath, Peter J ^e  

^a LENOIR RHYNE UNIVERSITY   (United States)

^b Frye Regional Medical Center   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f AUBURN UNIVERSITY   (United States)

Author keywords

Cardiovascular disease risk; Lipid profile; Lipoprotein particle number; Lipoprotein particle size; Lipoprotein subclasses; NMR analysis; Soy protein

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOFLAVONE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MILK PROTEIN; SOYBEAN PROTEIN; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADOLESCENT; ADULT; APOLIPOPROTEINS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; HUMANS; ISOFLAVONES; LIPASE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MILK PROTEINS; PARTICLE SIZE; RISK FACTORS; SOYBEAN PROTEINS;

EID: 44349086378     PISSN: 17155312     EISSN: None     Source Type: Journal    
DOI: 10.1139/H08-023     Document Type: Article

References (58)

1. Allen, J.K., Becker, D.M., Kwiterovich, P.O., Lindenstruth, K.A., and Curtis, C. 2007. Effect of soy protein-containing isoflavones on lipoproteins in postmenopausal women. Menopause, 14: 106-114. doi:10.1097/01.gme. 0000229572.21635.49. PMID:17019375.
2. American College of Sports Medicine. 2006. ACSM's guidelines for exercise testing and prescription. Lippincott, Williams, and Wilkins, Baltimore, Md. pp. 58-63.
3. Anderson, J.W., Johnstone, B.M., and Cook-Newell, M.E. 1995. Meta-analysis of the effects of soy protein intake on serum lipids. N. Engl. J. Med. 333: 276-282. doi:10.1056/NEJM199508033330502. PMID:7596371.
4. Anthony, M.S., Clarkson, T.B., Hughes, C.L.J., Morgan, T.M., and Burke, G.L. 1996. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J. Nutr. 126: 43-50. PMID:8558324.
5. Anthony, M.S., Clarkson, T.B., Bullock, B.C., and Wagner, J.D. 1997. Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys. Arterioscler. Thromb. Vasc. Biol. 17: 2524-2531. PMID:9409223.
6. Arora, A., Nair, M.G., and Strasburg, G.M. 1998. Antioxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch. Biochem. Biophys. 356: 133-141. doi:10.1006/abbi.1998.0783.
7. Bakhit, R.M., Klein, B.P., Essex-Sorlie, D., Ham, J.O., Erdman, J.W., and Potter, S.M. 1994. Intake of 25g of soybean protein with or without soybean fiber alters plasma lipids in men with elevated cholesterol concentrations. J. Nutr. 124: 213-222. PMID:8308570.
8. Berneis, K.K., and Krauss, R.M. 2002. Metabolic origins and clinical significance of LDL heterogeneity. J. Lipid Res. 43: 1363-1379. doi:10.1194/jlr.R200004-JLR200. PMID:12235168.
9. Blanche, P.J., Gong, E.L., Forte, T.M., and Nichols, A.V. 1981. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim. Biophys. Acta, 24: 408-419.
10. Caldwell, C.R., Britz, S.J., and Mirecki, R.M. 2005. Effect of temperature, elevated carbon dioxide, and draught during seed development on the isoflavone content of dwarf soybean [Glycine max (L.) Merrill] grown in controlled environments. J. Agric. Food Chem. 53: 1125-1129. doi:10.1021/jf0355351. PMID: 15713029.
11. Carroll, K.K., and Kurowska, E.M. 1995. Soy consumption and cholesterol reduction: review of animal and human studies. J. Nutr. 125: 594s-597s. PMID:7884539.
12. Cheung, M.C., and Albers, J.J. 1982. Distribution of high- densitylipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J. Lipid Res. 23: 747-753. PMID:6811682.
13. Clarkson, T.B. 2002. Soy, phytoestrogens and cardiovascular disease. J. Nutr. 132: 566s-569s. PMID:11880594.
14. Colvin, P., Moriguchi, E., Barrett, H., Parks, J., and Rudel, L. 1998. Production rate determines plasma concentration of large high density lipoprotein in non-human primates. J. Lipid Res. 39: 2076-2085. PMID:9788254.
15. Colvin, P.L., Moriguchi, E., Barrett, P.H.R., Parks, J.S., and Rudel, L.L. 1999. Small HDL particles containing two apo A-I molecules are precursors in vivo to medium and large HDL particles containing three and four apo A-I molecules in nonhuman primates. J. Lipid Res. 40: 1782-1792. PMID:10508197.
16. Coward, L., Smith, M., Kirk, M., and Barnes, S. 1998. Chemical modification of isoflavones in soy foods during cooking and processing. Am. J. Clin. Nutr. 68: 1486s-1491s. PMID:9848521.
17. Department of Health and Human Services. 1999. Food labeling: health claims; soy protein and coronary heart disease. Federal Regulations, No. 64(21 CFR Part 101): 57700-57733.
18. El Harchaoui, K., van der Steeg, W.A., Stroes, E.S., Kuivenhoven, J.A., Otvos, J.D., Wareham, N.J., et al. 2007. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women. J. Am. Coll. Cardiol. 49: 547-553.
19. Friedman, M., and Brandon, D.L. 2001. Nutritional and health benefits of soy proteins. J. Agric. Food Chem. 49: 1069-1086. doi:10.1021/jf0009246. PMID:11312815.
20. Goodman-Gruen, D., and Kritz-Silverstein, D. 2001. Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J. Nutr. 131: 1202-1206. PMID:11285326.
21. Greaves, K.A., Wilson, M.D., Rudel, L.L., Williams, J.K., and Wagner, J.D. 2000. Consumption of soy protein reduces cholesterol absorption compared to casein protein alone or supplemented with an isoflavone extract or conjugated equine estrogen in ovariectomized cynomolgus monkeys. J. Nutr. 130: 820-826. PMID:10736336.
22. Grundy, S.M. 1999. Primary prevention of coronary heart disease. Circulation, 100: 988-998. PMID:10468531.
23. Haffner, S.M., Applebaum-Bowden, D., and Wahl, P.W. 1985. Epidemiological correlates of high-density-lipoprotein subfractions; apolipoproteins A-I, A-II, and D; and lecithin cholesterol acyltransferase: effects of smoking, alcohol, and adiposity. Arteriosclerosis, 5: 169-177. PMID:3919701.
24. Haskell, W.L., Camargo, C., Williams, P.T., Vranizan, K.M., Krauss, R.M., Lindgren, F.T., et al. 1984. The effect of cessation and resumption of moderate alcohol intake on serum high-density-lipoprotein subfraction. A controlled study. N. Engl. J. Med. 310: 805-810. PMID:6366553.
25. Ho, H.T., Kim, D.N., and Lee, K.T. 1989. Intestinal apolipoprotein B-48 synthesis and lymphatic transport of cholesterol and oleic acid. Atherosclerosis, 77: 15-23. doi:10.1016/0021-9150(89)90004-X. PMID:2719758.
26. Hodgson, J.M., Puddey, I.B., Beilin, L.J., Mori, T.A., and Croft, K.D. 1998. Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomized controlled trial in humans. J. Nutr. 128: 728-732. PMID:9521635.
27. Johansson, J., Carlson, L.A., Landou, C., and Hamsten, A. 1991. High density lipoproteins and coronary atherosclerosis: a strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler. Thromb. 11: 174-182. PMID:1987996.
28. Keys, A. (Editor). 1970. Coronary heart disease in seven countries. Circulation, 41(Suppl. 1): 1-211. Available from http:// circ.ahajournals.org/content/vol41/issue4S1/. [Accessed January 2008.]
29. Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G.R., Lupien, P.J., et al. 1997. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular study. Circulation, 95: 69-75. PMID:8994419.
30. Lo, G.S., Goldberg, A.P., Lim, A., Grundhauser, J.J., Anderson, C., and Schonfeld, G. 1986. Soy fiber improves lipid and carbohydrate metabolism in primary hyperlipidemic subjects. Atherosclerosis, 62: 239-248. doi:10.1016/0021-9150(86)90098-5. PMID:3026411.
31. Lu, L.J., and Anderson, K.E. 1998. Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans. Am. J. Clin. Nutr. 68: 1500s-1504s. PMID:9848524.
32. Ma, Y., Chiriboga, D., Olendzki, B.C., Nicolosi, R., Merriam, P.A., and Ockene, I.S. 2005. Effect of soy protein containing isoflavones on blood lipids in moderately hypercholesterolemic adults: a randomized controlled trial. J. Am. Coll. Nutr. 24: 275-285. PMID:16093405.
33. McCarty, M.F. 1999. Vegan proteins may reduce risk of cancer, obesity, and cardiovascular disease by promoting increased glucagon activity. Med. Hypotheses, 53: 459-485. doi:10.1054/mehy.1999.0784. PMID:10687887.
34. Merz-Demlow, B.E., Duncan, A.M., Wangen, K.E., Xu, X., Carr, T.P., Phipps, W.R., Kurzer, M.S. 2000. Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. Am. J. Clin. Nutr. 71: 1462-1469.
35. Miller, N.E., Hammett, F., Saltissi, S., Rao, S., Van Zeller, H., Coltart, J., et al. 1981. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br. Med. J. (Clin. Res. Ed.), 282: 1741-1744. PMID:6786600.
36. Nagata, C., Takatsuka, N., Kurisu, Y., and Shimizu, H. 1998. Decreased serum total cholesterol concentration is associated with high intake of soy products in Japanese men and women. J. Nutr. 128: 209-213. PMID:9446845.
37. Nguyen, T.T. 1999. The cholesterol-lowering action of plant stanol esters. J. Nutr. 129: 2109-2112. PMID:10573535.
38. Otvos, J.D. 2002. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin. Lab. (Zaragoza), 48: 171-180.
39. Otvos, J.D., Jeyarajah, E.J., and Cromwell, W.C. 2002. Measurement issues related to lipoprotein heterogeneity. Am. J. Cardiol. 90: 22i-29i. doi:10.1016/S0002-9149(02)02632-2. PMID:12419478.
40. Otvos, J.D., Collins, D., Freedman, D.S., Shalaurova, I., Schaefer, E.J., McNamara, J.R., et al. 2006. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by Gemfibrozil therapy in the Veterans Affairs high-density lipoprotein intervention trial. Circulation, 113: 1556-1563. doi:10.1161/ CIRCULATIONAHA.105.565135. PMID:16534013.
41. Pischon, T., Girman, C.J., Sacks, F.M., Rifai, N., Stampfer, M.J., and Rimm, E.B. 2005. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation, 112: 3375-3383. doi:10.1161/CIRCULATIONAHA.104.532499. PMID:16316964.
42. Potter, S.M. 1998. Soy protein and cardiovascular disease: the impact of bioactive components in soy. Nutr. Rev. 56: 231-235. PMID:9735676.
43. Pownall, H.J., and Ehnholm, C. 2006. The unique role of apolipoprotein A-I in HDL remodeling and metabolism. Curr. Opin. Lipidol. 17: 209-213. doi:10.1097/01.mol.0000226110.66942.e8. PMID:16680023.
44. Reynolds, K., Chin, A., Lees, K.A., Nguyen, A., Bujnowski, D., and He, J. 2006. A meta-analysis of the effect of soy protein supplementation on serum lipids. Am. J. Cardiol. 98: 633-640. doi:10.1016/j.amjcard.2006.03.042. PMID:16923451.
45. Rifai, N., Warnick, G.R., and Dominiczak, M.H. 2000. Handbook of lipoprotein testing. American Association for Clinical Chemistry, Inc., Washington, D.C. pp. 311-328, 479-497.
46. Sacks, F.M., and Campos, H. 2003. Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J. Clin. Endocrinol. Metab. 88: 4525-4532. doi:10.1210/jc.2003-030636. PMID:14557416.
47. Sacks, F.M., Lichenstein, A., Horn, L.V., Harris, W., Kris-Etherton, P., and Winston, M. 2006. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for health professionals from the nutrition committee. Circulation, 113: 1034-1044. doi:10.1161/ CIRCULATIONAHA. 106.171052. PMID:16418439.
48. Setchell, K.D. 1998. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am. J. Clin. Nutr. 68(6 Suppl.): 1333S-1346S.
49. Sirtori, C.R., Calabresi, L., and Franceschini, G. 1999. Recombinant apolipoproteins for the treatment of vascular diseases. Atherosclerosis, 142: 29-40. doi:10.1016/S0021-9150(98)00247-0. PMID:9920503.
50. Slavin, J.L., Karr, S.C., Hutchins, A.M., and Lampe, J.W. 1998. Influence of soybean processing, habitual diet, and soy dose on urinary isoflavonoid excretion. Am. J. Clin. Nutr. 68: 1492s-1495s. PMID:9848522.
51. Taku, K., Umegaki, K., Sato, Y., Endoh, K., and Watanabe, S. 2007. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr. 85: 1148-1156. PMID:17413118.
52. Teixeira, S.R., Potter, S.M., Weigel, R., Hannum, S., Erdman, J.W., Jr., and Hasler, C.M. 2000. Effects of feeding 4 levels of soy protein for 3 and 6 week on blood lipids and apolipoproteins in moderately hypercholesterolemic men. Am. J. Clin. Nutr. 71: 1077-1084.
53. Van Horn, L., and Ernst, N. 2001. A summary of the science supporting the new National Cholesterol Education Program dietary recommendations: what dietitians should know. J. Am. Diet. Assoc. 101: 1148-1154. doi:10.1016/S0002-8223(01)00283-8. PMID:11678485.
54. Vessby, B., Karlstrom, B., Lithell, H., Gustafsson, I.B., and Werner, I. 1982. The effects on lipid and carbohydrate metabolism of replacing some animal protein by soy protein in a lipid-lowering diet for hypercholesterolemic patients. Hum. Nutr. Appl. Nutr. 36: 179-189. PMID:6889589.
55. Washburn, S., Burke, G.L., Morgan, T., and Anthony, M. 1999. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopasual symptoms in perimenopausal women. Menopause, 6: 7-13. doi:10.1097/00042192-199906010-00004. PMID:10100174.
56. Weissberg, P.L., and Rudd, J.H. 2002. Atherosclerotic biology and epidemiology of disease. In Textbook of cardiovascular medicine. Edited by E.J. Topol. Lippincott Williams Wilkins, Philadelphia, Pa. p. 6.
57. Williams, P.T., Krauss, R.M., Vranizan, K.M., Stefanick, M.L., Wood, P.D.S., and Lindgren, F.T. 1992. Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women. Arterioscler. Thromb. 12: 332-340. PMID:1547192.
58. Zhan, S., and Ho, S.C. 2005. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am. J. Clin. Nutr. 81: 397-408. PMID:15699227.